Compare Merck & Co., Inc. (MRK) vs iShares 0 3 Month Treasury Bond ETF (SGOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs iShares 0 3 Month Treasury Bond ETF — how do they compare? Merck & Co., Inc. trades at $146.31 (market cap $351.28B), while iShares 0 3 Month Treasury Bond ETF trades at $100.52 (market cap $114.40B). The key difference: Merck & Co., Inc. is far larger — about 3.1× iShares 0 3 Month Treasury Bond ETF's market cap, and Merck & Co., Inc. pays a 2.39% dividend while iShares 0 3 Month Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and iShares 0 3 Month Treasury Bond ETF for 50 Days on average.
| MRK | SGOV | |
|---|---|---|
Market Cap | $351.28B | $114.40B |
Volume | 7,969,665 | 18,879,081 |
Sector | Health | Fixed Income |
52-Week High | $156.43 | $100.72 |
52-Week Low | $82.49 | $100.28 |
Typical Hold Time | 98 Days | 50 Days |
Enterprise Value | $398.04B | — |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
SGOV trades at $100.515 with minimal daily movement (+0.05%). The technical outlook is bearish with moving averages signaling selling pressure, though oscillators are neutral. Recent dividends of $0.30-0.31 per share were declared for H2-2026. The ETF focuses on short-term Treasury bonds, with institutional activity showing Envestnet reduced its position by 13.2% in Q2 2026.
The outlook remains cautious amid rising Treasury yields and bond market volatility. Higher interest rates could pressure short-term bond ETFs like SGOV, though they offer relative safety. Key risks include Fed policy shifts and inflation trends. Investors should weigh yield advantages against duration risk in the current rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →
